David Scott Jones - 09 Feb 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2022
Net transactions value
-$14,921
Form type
4
Filing time
11 Feb 2022, 15:39:07 UTC
Previous filing
03 Nov 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4,966 +54% $0.000000 14,097 09 Feb 2022 Direct F1
transaction EYPT Common Stock Tax liability $14,921 -1,473 -10% $10.13 12,624 09 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +15,000 $0.000000 15,000 09 Feb 2022 Common Stock 15,000 $0.000000 Direct F3
transaction EYPT Restricted Stock Units Options Exercise $0 -4,966 -33% $0.000000 9,934 09 Feb 2022 Common Stock 4,966 $0.000000 Direct F4
transaction EYPT Stock Option (Right to Buy) Award $0 +60,000 $0.000000 60,000 09 Feb 2022 Common Stock 60,000 $10.13 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 886 shares acquired on July 30, 2021 and 865 shares acquired on January 31,2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F3 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F4 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
F5 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.